Drug Interaction Study of LOXO-305 and Digoxin in Healthy Subjects

Phase 1, open-label, single-arm trial of pirtobrutinib in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma at Day 16, Area Under the Concentration During a Dosing Interval (AUC [Tau]) of Digoxin in Plasma at Day 16 and 13 more. Started Mar 2021; status: completed.